1-3 of 3
Sue E. Bell, DPhil
Close
Sort by
Journal Articles

Sequential Immunomodulatory Drug (IMiD) and Proteosome Inhibitor Therapy Improves Response Rates in Newly Diagnosed Multiple Myeloma: Preliminary Results From the Myeloma XI Trial

Charlotte Pawlyn, MD, Faith E. Davies, MD, Walter M Gregory, PhD, Alex J Szubert, MSc, Sue E Bell, DPhil, Jacqueline Ouzman, PhD, Mark T Drayson, MD, Roger G Owen, MD, Graham H Jackson, MD, Nigel H Russell, MD, Gareth J. Morgan, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 335.
https://doi.org/10.1182/blood.V120.21.335.335
Published: 2012
Journal Articles

MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease

Gareth J Morgan, MD PhD, Faith E Davies, MD, Walter M Gregory, PhD, Sue E Bell, DPhil, Alex J Szubert, MSc, Gordon Cook, Mark T Drayson, MD, Roger G Owen, MD, Fiona M Ross, DPhil, Graham H Jackson, MD, J. Anthony Child, MD
Journal: Blood
Blood (2011) 118 (21): 993.
https://doi.org/10.1182/blood.V118.21.993.993
Published: 2011
Journal Articles

Optimising Bone Disease In Myeloma; Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints: Results of the MRC Myeloma IX Trial

Gareth J Morgan, MD, PhD, Faith E. Davies, MD, Walter M Gregory, Sue E. Bell, DPhil, Alexander J Szubert, MSc, Mark T. Drayson, MD, John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Roger G. Owen, MD, Gordon Cook, MD, Fiona M. Ross, Dr, Graham H. Jackson, MD, Nigel H. Russell, MD, J. Anthony Child, MD
Journal: Blood
Blood (2010) 116 (21): 311.
https://doi.org/10.1182/blood.V116.21.311.311
Published: 2010